Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
Authors
Abstract:
Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment.Trial registration: ANZCTR registration ID: ACTRN12610000621011.
similar resources
evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial
hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. this study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. in a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. the intervention group was assigned to receive silymarin and the control group received placebo. tuberculosis...
full textSilymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial
Abstract Background: No pharmacologic agents have been approved for the treatment of non-alcoholic steatohepatitis (NASH) that is common in our region. The present study was designed to evaluate the efficacy of silymarin, a known herbal drug, in the treatment of NASH. Methods: This clinical-trial study was conducted on 64 patients with NASH who were randomly divided as case group (33) and con...
full textEffect of Statin Treatment on COVID-19 Patients’ Outcomes: A Randomized Double-blind Controlled Clinical Trial
Background: Statins may be protective against viral infection and have been suggested for the treatment of coronavirus disease 2019 (COVID-19). Objective: In this study, we aimed to evaluate the effect of atorvastatin on COVID-19 patients. Methods: Our study is a randomized double-blind controlled clinical trial that constitutes a population of COVID-19 patients admitted to Bu-Ali Sina Hospi...
full textDeferoxamine Protective Effect in Preventing Nephrotoxicity in Children Under Treatment with Doxorubicin: A Randomized Clinical Trial
Background: Nephrotoxicity secondary to doxorubicin (DOX) may be associated with high morbidity and mortality rates. We aimed to assess the efficacy of Deferoxamine (DFO) in preventing DOX-induced nephrotoxicity in pediatric malignancy. Methods: This Parallel-group randomized clinical trial was done on 62 children aged 2-18 years who had new onset malignancy treated with DOX. They were randoml...
full textMy Resources
Journal title
volume 15 issue 1
pages 247- 252
publication date 2016-02-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023